Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Carmel AwadallahDivision of Internal Medicine, St John Episcopal Hospital, Far Rockaway, NY 11691, USA.
Anas ZayadDepartment of Internal Medicine, Hamad Medical Corporation, Doha 3050, Qatar.ORCID 0009-0006-7537-0112
Shebli AtrashLevine Cancer Center, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28204, USA.ORCID 0000-0003-4547-7534
Anita MazloomDivision of Hematology and Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.ORCID 0009-0009-7899-7078
Omar AlkharabshehDivision of Hematology and Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.ORCID 0000-0002-5299-4233
Prerna MewawallaDivision of Hematology and Bone Marrow Transplant, Alleghany Medical Center, Pittsburg, PA 15212, USA.ORCID 0009-0008-7464-6898
Mansi R ShahDivision of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ 08903, USA.
Forat LutfiDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0002-9699-3080
Zahra MahmoudjafariDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0002-3168-2521
Muhammad Umair MushtaqDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.
Jeries KortDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0001-9182-3931
Alma HabibDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.
Al-Ola AbdallahDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0002-6603-185X
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis. · full record | OpenQuestion